Biovie (BIVI) Retained Earnings (2013 - 2026)
Biovie (BIVI) posted Retained Earnings of -$368.6 million for Q1 2026, down 1.45% sequentially from -$363.3 million in Q4 2025, and down 5.72% YoY from -$391.0 million in Q1 2025.
Biovie (BIVI) Retained Earnings (2013 - 2026) Analysis & Trends
Biovie has reported Retained Earnings for 14 years, with the latest figure at -$368.6 million in Q1 2026.
- Quarterly Retained Earnings fell 5.72% year-over-year to -$368.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$368.6 million (down 5.72% YoY) and the FY2025 annual result came in at -$352.1 million, down 5.36% from the prior year.
- Retained Earnings fell to -$368.6 million in Q1 2026 per BIVI's latest filing, from -$363.3 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$242.9 million in Q1 2022 and troughed at -$368.6 million in Q1 2026.
- A 5-year average of -$317.4 million and a median of -$329.3 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings plunged 160.18% in 2022, then retreated 5.05% in 2025.
- Over 5 years, Retained Earnings stood at -$277.1 million in 2022, then slipped by 15.62% to -$320.3 million in 2023, then dropped by 7.97% to -$345.9 million in 2024, then retreated by 5.05% to -$363.3 million in 2025, then fell by 1.45% to -$368.6 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$368.6 million, -$363.3 million, and -$357.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | 374.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -374.26 Mn |
| Mar 31, 2026 | -368.62 Mn |
| Dec 31, 2025 | -363.34 Mn |
| Sep 30, 2025 | -357.28 Mn |
| Jun 30, 2025 | -352.14 Mn |
| Mar 31, 2025 | -348.66 Mn |
| Dec 31, 2024 | -345.87 Mn |
| Sep 30, 2024 | -338.71 Mn |
| Jun 30, 2024 | -334.23 Mn |
| Mar 31, 2024 | -329.29 Mn |
| Dec 31, 2023 | -320.34 Mn |
| Sep 30, 2023 | -311.94 Mn |
| Jun 30, 2023 | -301.23 Mn |
| Mar 31, 2023 | -292.11 Mn |
| Dec 31, 2022 | -277.07 Mn |
| Sep 30, 2022 | -261.39 Mn |
| Jun 30, 2022 | -250.97 Mn |
| Mar 31, 2022 | -242.88 Mn |
| Dec 31, 2021 | -235.84 Mn |
| Sep 30, 2021 | -230.43 Mn |